![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 23, 2019 4:35:42 PM
https://www.sec.gov/Archives/edgar/data/1659617/000114420419016728/0001144204-19-016728-index.htm
As of 3 weeks ago, the company has 75 Million authorized shares that they could unload onto us at their choosing. That's exactly what happened today. Ignore the 29M OS figure you see. It's much higher now. The updated OS will be reflected in the next filing.
If tomorrow ends up a nothingburger, than the company was smart to dump the hell out of their newly created outstanding shares today.
If tomorrow ends up genuine (unlikely), than the actors involved were not well coordinated and shortsold themselves and everyone else here prematurely.
You're welcome.
GLTA.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:00:40 PM
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Moleculin to Present at the Virtual Investor Pitch Conference • PR Newswire (US) • 06/12/2024 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:05:48 PM
- Moleculin to Participate in the Virtual Investor Lunch Break Series • PR Newswire (US) • 06/05/2024 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/13/2024 02:53:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:14 AM
- Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:55:19 PM
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data • PR Newswire (US) • 05/07/2024 12:55:00 PM
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 • PR Newswire (US) • 05/02/2024 01:00:00 PM
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 05/01/2024 12:50:00 PM
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM